拓扑替康对人卵巢癌细胞株端粒酶活性表达的影响-东南大学学报医学版

拓扑替康对人卵巢癌细胞株端粒酶活性表达的影响

单位：东南大学附属中大医院,妇产科,江苏,南京,210009

分类号：R969.4, R737.31

出版年·卷·期（页码）：2005·24·第二期（78-81）

摘要：

目的:探讨拓扑替康对卵巢癌细胞端粒酶活性表达的影响.方法:用TRAP-ELISA法检测浓度为26 000μg·L-1的盐酸拓扑替康(和美新)作用于卵巢癌HO-8910细胞株不同时间后端粒酶活性的改变,并以流式细胞检测法同步检测细胞凋亡及细胞周期改变.结果:随着拓扑替康作用时间的延长,HO-8910细胞株的凋亡率逐渐增加,而端粒酶活性逐渐降低.当作用达60h后,细胞凋亡达47.62%时端粒酶活性呈阴性.结论:端粒酶活性抑制不是拓扑替康诱导卵巢癌细胞凋亡的直接原因,但临床监测端粒酶活性表达有助于对盐酸拓扑替康抗卵巢癌的疗效进行客观评价.

Objective To evaluate the effect of topotecan on telomerase activity expression in human ovarian cancer cells. Methods TRAP-ELISA assay was used to study the changes of telomerase of HO-8910 cell line activated by topotecan hydrochloride after different period, and flow cytometry method was applied to detect the cell apoptosis and the changes of cell cycle in the same time.Results The apoptosis rate of HO-8910 cell line rose gradually, while telomerase activity reduced progressively along with the activating time. The telomerase activity was completely inhibited while the cell apoptosis reached 47.62% after 60 hours. Conclusions The inhibition of telomerase activity does not directly result from apoptosis induced by chemotherapeutic drug topotecan in ovarian cancer treatment. Measuring telomerase activity can be the clinical index in objectively evaluating the curative effect of topotecan.

参考文献：

[1] 郎景和, 张震宇. 卵巢上皮癌的化学治疗, 2000
[2] 任慕兰, 沈杨, 彭素蓉. 人卵巢肿瘤组织中端粒酶活性表达的研究及临床意义. 东南大学学报(医学版)2002(1). doi:10.3969/j.issn.1671-6264.2002.01.017
[3] HERBERT B S, WRIGHT A C, PASSONS C M. Effects of chenoprevention and antitelomerase agents on the spontaneous immortalization of breast epithelial cells, 2001(1)
[4] ZHU X, KUMAR R, MANDAL M. Cell cycle-dependent modulation of telomerase activity in tumor cells. 1996(12)
[5] FIORICA J, HOLLOWAY R, NDUBISI B. Phase Ⅱ trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. 2002(1). doi:10.1006/gyno.2001.6557
[6] 孟志强, 宋明志, 黄雯霞. 多种药物对肝癌细胞端粒酶活性的影响. 癌症2000(4). doi:10.3321/j.issn:1000-467X.2000.04.009
[7] 李善华, 杨芳, 宋琳. 盐酸拓扑替康联合顺铂治疗晚期卵巢上皮癌的临床观察. 现代妇产科进展2002(4). doi:10.3969/j.issn.1004-7379.2002.04.022
[8] BOOKMAN M A. Developmental chemotherapy in advanced ovarian cancer:incorporation of newer cytotoxic agents in a phase Ⅲrandomized trial of the Gynecologic Oncology Group (GOG-O182). 2002(z1)

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录